Ace­lyrin re­jects buy­out of­fer from Tang’s Con­cen­tra, sticks to Alu­mis merg­er

The board of im­munol­o­gy biotech Ace­lyrin has re­ject­ed the buy­out of­fer from Tang Cap­i­tal’s shell com­pa­ny Con­cen­tra Bio­sciences, clear­ing up any doubt about its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER